[1]Hu,Bin;Toda,Kosuke;Wang,Xiaoyu;Antczak,MonikaI.;Smith,Julianne;Geboers,Sophie;Nishikawa,Gen;Li,Hongyun;Dawson,Dawn;Fink,Stephen;Desai,AmarB.;Williams,NoelleS.;Markowitz,SanfordD.;Ready,JosephM.[JournalofMedicinalChemistry,2022,vol.65,#22,p.15327-15343]
[1]Hu,Bin;Toda,Kosuke;Wang,Xiaoyu;Antczak,MonikaI.;Smith,Julianne;Geboers,Sophie;Nishikawa,Gen;Li,Hongyun;Dawson,Dawn;Fink,Stephen;Desai,AmarB.;Williams,NoelleS.;Markowitz,SanfordD.;Ready,JosephM.[JournalofMedicinalChemistry,2022,vol.65,#22,p.15327-15343]
[1]Hu,Bin;Toda,Kosuke;Wang,Xiaoyu;Antczak,MonikaI.;Smith,Julianne;Geboers,Sophie;Nishikawa,Gen;Li,Hongyun;Dawson,Dawn;Fink,Stephen;Desai,AmarB.;Williams,NoelleS.;Markowitz,SanfordD.;Ready,JosephM.[JournalofMedicinalChemistry,2022,vol.65,#22,p.15327-15343]
[1]Hu,Bin;Toda,Kosuke;Wang,Xiaoyu;Antczak,MonikaI.;Smith,Julianne;Geboers,Sophie;Nishikawa,Gen;Li,Hongyun;Dawson,Dawn;Fink,Stephen;Desai,AmarB.;Williams,NoelleS.;Markowitz,SanfordD.;Ready,JosephM.[JournalofMedicinalChemistry,2022,vol.65,#22,p.15327-15343]
[1]Hu,Bin;Toda,Kosuke;Wang,Xiaoyu;Antczak,MonikaI.;Smith,Julianne;Geboers,Sophie;Nishikawa,Gen;Li,Hongyun;Dawson,Dawn;Fink,Stephen;Desai,AmarB.;Williams,NoelleS.;Markowitz,SanfordD.;Ready,JosephM.[JournalofMedicinalChemistry,2022,vol.65,#22,p.15327-15343]
Title: Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review.
Journal: Schizophrenia bulletin 20120901
Title: Glutamatergic targets for enhancing extinction learning in drug addiction.
Journal: Current neuropharmacology 20101201
Title: Positive allosteric modulators of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor.
Journal: Journal of medicinal chemistry 20101028
Title: Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats.
Journal: Behavioural brain research 20100211
Title: Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting.
Journal: Psychopharmacology 20091101
Title: Systematic review of pharmacological treatments in fragile X syndrome.
Journal: BMC neurology 20090101
Title: Ampakine CX516 ameliorates functional deficits in AMPA receptors in a hippocampal slice model of protein accumulation.
Journal: Experimental neurology 20081101
Title: Glutamate receptor-mediated restoration of experience-dependent place field expansion plasticity in aged rats.
Journal: Behavioral neuroscience 20080601
Title: A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.
Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20080201
Title: Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial.
Journal: Journal of child and adolescent psychopharmacology 20061001
Title: Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats.
Journal: Pharmacology, biochemistry, and behavior 20060601
Title: Glutamate-based therapeutic approaches: ampakines.
Journal: Current opinion in pharmacology 20060201
Title: Positive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulators have different impact on synaptic transmission in the thalamus and hippocampus.
Journal: The Journal of pharmacology and experimental therapeutics 20050401
Title: Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data.
Journal: Psychopharmacology 20050401
Title: Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis.
Journal: Schizophrenia research 20050101
Title: Amphetamine-evoked gene expression in striatopallidal neurons: regulation by corticostriatal afferents and the ERK/MAPK signaling cascade.
Journal: Journal of neurochemistry 20041001
Title: Modulation of AMPA receptor kinetics differentially influences synaptic plasticity in the hippocampus.
Journal: Neuroscience 20040101
Title: Cortex Pharmaceuticals, Inc. Maintaining brain function goes a long way.
Journal: Chemistry & biology 20031101
Title: LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.
Journal: The Journal of pharmacology and experimental therapeutics 20030801
Title: Benzamide-type AMPA receptor modulators form two subfamilies with distinct modes of action.
Journal: The Journal of pharmacology and experimental therapeutics 20021201
Title: Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type glutamate receptors elicits neuroprotection after trimethyltin exposure in hippocampus.
Journal: Toxicology and applied pharmacology 20021201
Title: Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series.
Journal: Schizophrenia research 20021001
Title: Positive modulators of AMPA receptors as a potential treatment for schizophrenia.
Journal: Current opinion in investigational drugs (London, England : 2000) 20020701
Title: CX-516 Cortex pharmaceuticals.
Journal: Current opinion in investigational drugs (London, England : 2000) 20020701
Title: Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model.
Journal: European journal of pharmacology 20020405
Title: Survival signaling and selective neuroprotection through glutamatergic transmission.
Journal: Experimental neurology 20020301
Title: Randomized, double-blind, placebo-controlled international clinical trial of the Ampakine CX516 in elderly participants with mild cognitive impairment: a progress report.
Journal: Journal of molecular neuroscience : MN 20020101
Title: Mechanism and impact of allosteric AMPA receptor modulation by the ampakine CX546.
Journal: Neuropharmacology 20011101
Title: A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia.
Journal: Journal of clinical psychopharmacology 20011001
Title: Therapeutic approaches to age-associated neurocognitive disorders.
Journal: Dialogues in clinical neuroscience 20010901
Title: Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors in prefrontal cortical pyramidal neurons by a novel allosteric potentiator.
Journal: The Journal of pharmacology and experimental therapeutics 20010701
Title: Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro.
Journal: Neuropharmacology 20010601
Title: Potentiation of responses to AMPA on central neurones by LY392098 and LY404187 in vivo.
Journal: Neuropharmacology 20010601
Title: AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys.
Journal: Neurology 20000425
Title: Synergistic interactions between ampakines and antipsychotic drugs.
Journal: The Journal of pharmacology and experimental therapeutics 19990401
Title: Effects of AMPA receptor positive modulators on amphetamine- and dizocilpine-induced locomotion.
Journal: European journal of pharmacology 19970806
Title: Broberg BV, Glenth?j BY, Dias R, et al. Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting. Psychopharmacology (Berl). 2009 Nov;206(4):631-40.
